As said before, the therapeutic strategy is applicable to DS patients with SCN1A LOF variants (e.g., truncating, nonsense, frameshift, or deletions) whose mutant alleles are subject to nonsense-mediated decay. This evidence concerns the gene SCN1A and Dravet syndrome.